Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Forest Memantine Shows Small But Consistent Effect In Alzheimer’s – Cmte.

Executive Summary

Forest memantine (Namenda) has a small but consistent effect in patients with moderate to severe Alzheimer's dementia, FDA's Peripheral & Central Nervous System Drugs Advisory Committee concluded Sept. 25
Advertisement

Related Content

Forest Namenda Clears FDA; Alzheimer Drug Shipments To Begin In December
Forest Namenda Clears FDA; Alzheimer Drug Shipments To Begin In December
Forest Memantine Plans Include Expanded Mild Alzheimer’s Indication
Forest Memantine Plans Include Expanded Mild Alzheimer’s Indication
Lundbeck Serlect NDA Revival Is One Project For CEO-Elect Braestrup
Lundbeck Serlect NDA Revival Is One Project For CEO-Elect Braestrup
Forest Counting On Memantine, Benicar, To Bolster Growth Post-Celexa  
Forest Counting On Memantine, Benicar, To Bolster Growth Post-Celexa  
Advertisement
UsernamePublicRestriction

Register

PS042535

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel